Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    DWN12088

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Daewoong's Bersiporocin Receives Positive IDMC Recommendation
    Daewoong's Bersiporocin Receives Positive IDMC Recommendation

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-receives-positive-recommendation-from-idmc-to-continue-developing-its-first-in-class-prs-inhibitor-bersiporocin-302208388.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    Daewoong's Bersiporocin Receives 'Orphan Drug Designation' in Europe
    Daewoong's Bersiporocin Receives 'Orphan Drug Designation' in Europe

    29 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/daewoong-pharmaceuticals-bersiporocin-receives-orphan-drug-designation-in-europe-to-treat-idiopathic-pulmonary-fibrosis-302046419.html

    PR NEWSWIRE
    29 Jan 2024
    Share Share
    Daewoong Pharmaceutical begins the first administration of the Bersiporocin
    Daewoong Pharmaceutical begins the first administration of the Bersiporocin

    06 Feb 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-begins-the-first-administration-of-the-bersiporocin-new-treatment-for-idiopathic-pulmonary-fibrosis-as-phase-ii-clinical-trial-301739041.html

    PR NEWSWIRE
    06 Feb 2023
    Share Share